L-692,429 vs hGHRH(1-37)OH
Head-to-head comparison of L-692,429 (L-692,429) and hGHRH(1-37)OH (Human growth hormone-releasing factor (1-37) hydroxyl) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | L-692,429 | hGHRH(1-37)OH |
|---|---|---|
| Category | Growth Hormone | Growth Hormone |
| Full Name | L-692,429 | Human growth hormone-releasing factor (1-37) hydroxyl |
| Molecular Weight | N/A | N/A |
| Half-Life | unknown / study-dependent | 5-20 minutes |
| Amino Acids | N/A | 37 |
| Typical Dose | 0.03-0.1 mg/kg | 1-2 mcg/kg |
| Route | Oral | Subcutaneous/IV |
| Purity | ≥98% | ≥98% |
| Studies Count | 30 | 60 |
| Research Status | Pre-clinical | Clinical Research |
L-692,429 Benefits
- ✓potent GHSR agonism
- ✓oral bioactivity in models
- ✓validates ghrelin pathway
- ✓useful research probe
hGHRH(1-37)OH Benefits
- ✓GH release studies
- ✓minimal-sequence mapping
- ✓receptor pharmacology
- ✓peptide stability research
L-692,429 Dosing
0.03-0.1 mg/kg in early studies|single oral or short-course research dosing|serial GH sampling recommended
hGHRH(1-37)OH Dosing
1-2 mcg/kg SC or IV bolus|acute stimulation with serial GH assays|short-course research administration with biomarker monitoring
L-692,429 Side Effects
- ⚠increased appetite
- ⚠glucose intolerance
- ⚠transient prolactin changes
hGHRH(1-37)OH Side Effects
- ⚠flushing
- ⚠headache
- ⚠transient fatigue
Research Overview
L-692,429
L-692,429 was important in early GH secretagogue research because it showed that nonpeptide molecules could trigger robust GH release. It remains a classic tool compound for studying receptor-mediated GH pulsatility and appetite signaling.
hGHRH(1-37)OH
Human GHRF(1-37)OH has appeared in studies examining how loss of C-terminal residues affects biological activity at the GHRH receptor. It is often used alongside other fragments to define structure-activity relationships within the GHRH family.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.